NCT00293709

Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists

Prospective Post Marketing Surveillance To Evaluate The Safety And Efficacy Of Etanercept Under Usual Care Settings In Patients With Psoriatic Arthritis (Psa) Treated By Dermatologists

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 129 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety profile and the effectiveness of etanercept under usual care settings in patients with PsA treated by dermatologists.

Detailed description

Non-interventional study: subjects to be selected according to the usual clinical practice of their physician

Conditions

• Arthritis, Psoriatic
• Psoriasis
• Skin Diseases, Papulosquamous

Interventions

Type	Name	Description
DRUG	etanercept	The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Timeline

• Start date: 2006-01-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2006-02-17
• Last updated: 2014-02-26
• Results posted: 2014-02-26

Locations

1 site across 1 country: Germany